1 October 2001 in Journal of Medicinal Chemistry
7 April 2009 in Organic & Biomolecular Chemistry
In this article, we address the presence of the prekinamycin quinone methide using the techniques of spectral global fitting and the13C-labeling of the reactive centre. Two-electron reduction of a prekinamycin affords a long-lived quinone methide species that was characterised spectrally. A correlation was made between the calculated ΔE (kcal/mol) values for quinone methide tautomerisation and cytostatic activity to support the postulate that the quinone methide plays a role in prekinamycin biological activity. We also prepared a stable quinone methide of prekinamycin and studied its solution chemistry directly.
1 October 1998 in Biochemistry
5 November 2002 in Journal of Medicinal Chemistry
1 June 1998 in Expert Opinion on Therapeutic Patents
This review presents a discussion of the design, chemistry, cytotoxicity and antitumour activity of agents based on the pyrrolobenzimidazole or azomitosene ring system. The focus is the 6-aziridinylquinone derivatives (PBIs) and 6-acetamidoquinone derivatives (APBIs) of this ring system (see Figure 1). Comparisons will be made with related benzimidazole and indole-based antitumour agent systems reported in the patent literature. The pyrrolobenzimidazoles will be shown to represent a new and useful class of antitumour agent with advantages over other such agents. The 6-aziridinyl derivatives (PBIs) alkylate and cleave DNA upon two-electron reduction as a result of phosphate alkylation by the protonated aziridine ring. In contrast, the 6-acetamido quinone derivatives (APBIs) do not require reductive activation to exert cytotoxicity. The 6-acetamido quinone derivatives act as DNA intercalating agents and inhibit the first step of topoisomerase II-mediated DNA relaxation. Some PBIs were found to exhibit high ...